Published in Biochem J on December 23, 2009
Enzyme kinetics and distinct modulation of the protein kinase N family of kinases by lipid activators and small molecule inhibitors. Biosci Rep (2014) 0.81
Regulation of protein kinase C-related protein kinase 2 (PRK2) by an intermolecular PRK2-PRK2 interaction mediated by Its N-terminal domain. J Biol Chem (2012) 0.79
Protein Kinase C-Related Kinase (PKN/PRK). Potential Key-Role for PKN1 in Protection of Hypoxic Neurons. Curr Neuropharmacol (2014) 0.77
Opportunities to Target Specific Contractile Abnormalities with Smooth Muscle Protein Kinase Inhibitors. Pharmaceuticals (Basel) (2010) 0.75
Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol (2008) 8.99
Protein kinase recognition sequence motifs. Trends Biochem Sci (1990) 7.49
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem (1997) 6.52
A rapid method for determining protein kinase phosphorylation specificity. Nat Methods (2004) 5.04
Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem (2000) 4.02
Determination of the specific substrate sequence motifs of protein kinase C isozymes. J Biol Chem (1997) 3.86
A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med (2003) 3.45
Identification of a putative target for Rho as the serine-threonine kinase protein kinase N. Science (1996) 3.09
Protein kinase N (PKN) and PKN-related protein rhophilin as targets of small GTPase Rho. Science (1996) 2.99
Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther (2004) 2.82
Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes (2001) 2.61
Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol (2007) 2.50
Protein kinases. Regulation by autoinhibitory domains. J Biol Chem (1990) 2.21
High-resolution multi-dimensional NMR spectroscopy of proteins in human cells. Nature (2009) 2.06
Determining protein kinase substrate specificity by parallel solution-phase assay of large numbers of peptide substrates. Nat Protoc (2006) 1.83
Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv Drug Deliv Rev (2004) 1.81
Direct and rapid cytosolic delivery using cell-penetrating peptides mediated by pyrenebutyrate. ACS Chem Biol (2006) 1.79
A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J Neurosci (2003) 1.68
Molecular transporters for peptides: delivery of a cardioprotective epsilonPKC agonist peptide into cells and intact ischemic heart using a transport system, R(7). Chem Biol (2001) 1.58
A myristoylated pseudosubstrate peptide, a novel protein kinase C inhibitor. J Biol Chem (1993) 1.58
Substrate discrimination among mitogen-activated protein kinases through distinct docking sequence motifs. J Biol Chem (2008) 1.57
The structure and function of PKN, a protein kinase having a catalytic domain homologous to that of PKC. J Biochem (2003) 1.51
Fyn tyrosine kinase is a downstream mediator of Rho/PRK2 function in keratinocyte cell-cell adhesion. J Cell Biol (2002) 1.48
Kinase peptide specificity: improved determination and relevance to protein phosphorylation. Proc Natl Acad Sci U S A (2004) 1.43
A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer. EMBO J (2003) 1.32
Oligoarginine vectors for intracellular delivery: design and cellular-uptake mechanisms. Biopolymers (2006) 1.28
Role of basic residues in the phosphorylation of synthetic peptides by myosin light chain kinase. Proc Natl Acad Sci U S A (1983) 1.26
The Drosophila Pkn protein kinase is a Rho/Rac effector target required for dorsal closure during embryogenesis. Genes Dev (1999) 1.24
Identification of new kinase clusters required for neurite outgrowth and retraction by a loss-of-function RNA interference screen. Cell Death Differ (2007) 1.21
Rho GTPases regulate PRK2/PKN2 to control entry into mitosis and exit from cytokinesis. EMBO J (2007) 1.19
D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke (2004) 1.16
Activation of PKN, a novel 120-kDa protein kinase with leucine zipper-like sequences, by unsaturated fatty acids and by limited proteolysis. Biochem Biophys Res Commun (1994) 1.15
Blocking c-Jun-N-terminal kinase signaling can prevent hearing loss induced by both electrode insertion trauma and neomycin ototoxicity. Hear Res (2006) 1.14
A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo. Am J Physiol Heart Circ Physiol (2006) 1.08
PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J (2004) 1.06
Novel strategy for treatment of viral central nervous system infection by using a cell-permeating inhibitor of c-Jun N-terminal kinase. J Virol (2007) 1.01
Hyaluronan-CD44 interaction stimulates Rac1 signaling and PKN gamma kinase activation leading to cytoskeleton function and cell migration in astrocytes. J Neurochem (2007) 0.99
Mutational analysis of the regulatory mechanism of PKN: the regulatory region of PKN contains an arachidonic acid-sensitive autoinhibitory domain. J Biochem (1999) 0.98
Phosphorylation of tau is regulated by PKN. J Biol Chem (2000) 0.97
Roles of PDK-1 and PKN in regulating cell migration and cortical actin formation of PTEN-knockout cells. Oncogene (2004) 0.97
Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene (2003) 0.96
A protein kinase, PKN, accumulates in Alzheimer neurofibrillary tangles and associated endoplasmic reticulum-derived vesicles and phosphorylates tau protein. J Neurosci (1998) 0.93
A highly potent and selective PKCalpha inhibitor generated via combinatorial modification of a peptide scaffold. J Am Chem Soc (2004) 0.93
Ductal injection of JNK inhibitors before pancreas preservation prevents islet apoptosis and improves islet graft function. Hum Gene Ther (2009) 0.92
Phosphorylation events associated with different states of activation of a hepatic cardiolipin/protease-activated protein kinase. Structural identity to the protein kinase N-type protein kinases. J Biol Chem (1996) 0.91
D-JNKi, a peptide inhibitor of c-Jun N-terminal kinase, promotes functional recovery after transient focal cerebral ischemia in rats. Neuroscience (2008) 0.91
Peptides targeting protein kinases: strategies and implications. Physiology (Bethesda) (2006) 0.89
Regulation of a mitogen-activated protein kinase kinase kinase, MLTK by PKN. J Biochem (2003) 0.87
PKN delays mitotic timing by inhibition of Cdc25C: possible involvement of PKN in the regulation of cell division. Proc Natl Acad Sci U S A (2001) 0.87
Deregulation of PKN1 activity disrupts neurofilament organisation and axonal transport. FEBS Lett (2008) 0.86
Protein kinase PKN1 associates with TRAF2 and is involved in TRAF2-NF-kappaB signaling pathway. Biochem Biophys Res Commun (2004) 0.84
PKN activation via transforming growth factor-beta 1 (TGF-beta 1) receptor signaling delays G2/M phase transition in vascular smooth muscle cells. Cell Cycle (2007) 0.84
Impaired tight junction sealing and precocious involution in mammary glands of PKN1 transgenic mice. J Cell Sci (2007) 0.83
PRK1 phosphorylates MARCKS at the PKC sites: serine 152, serine 156 and serine 163. FEBS Lett (1996) 0.83
A rho-binding protein kinase C-like activity is required for the function of protein kinase N in Drosophila development. Genetics (2007) 0.83
Purification and kinase assay of PKN. Methods Enzymol (2006) 0.79
Possible regulation of intermediate filament proteins by Rho-binding kinases. Subcell Biochem (1998) 0.76
N-myristyl-Lys-Arg-Thr-Leu-Arg: a novel protein kinase C inhibitor. Biochem Pharmacol (1990) 0.76
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature (2008) 18.20
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res (2003) 15.74
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65
Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A (2004) 10.78
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature (2008) 9.77
Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol (2003) 8.25
Bidirectional transport of amino acids regulates mTOR and autophagy. Cell (2009) 7.88
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell (2003) 7.42
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell (2003) 7.04
Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science (2003) 6.97
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A (2005) 6.35
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science (2011) 5.73
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science (2011) 5.72
A PtdInsP(3)- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity. Nat Cell Biol (2002) 5.58
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science (2010) 5.44
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res (2005) 5.07
A rapid method for determining protein kinase phosphorylation specificity. Nat Methods (2004) 5.04
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A (2002) 4.93
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
Protein sequences from mastodon and Tyrannosaurus rex revealed by mass spectrometry. Science (2007) 4.41
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst (2005) 4.19
Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell (2010) 4.07
Rheb fills a GAP between TSC and TOR. Trends Biochem Sci (2003) 3.90
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell (2009) 3.85
Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol (2002) 3.68
The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr Biol (2004) 3.54
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol (2012) 3.40
The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell (2003) 3.36
Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev (2009) 3.35
Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev (2005) 3.25
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol (2009) 3.24
Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature (2016) 3.13
Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol Cell Biol (2005) 3.09
The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A (2010) 3.08
Lin28 enhances tissue repair by reprogramming cellular metabolism. Cell (2013) 3.08
Retracted Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J Biol Chem (2003) 3.06
The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell (2005) 3.05
Hem-1 complexes are essential for Rac activation, actin polymerization, and myosin regulation during neutrophil chemotaxis. PLoS Biol (2006) 3.01
Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol Cell (2011) 2.99
Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science (2012) 2.98
Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival. Cell (2011) 2.98
PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A (2010) 2.91
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol (2012) 2.87
Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther (2004) 2.82
Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab (2006) 2.82
Acute effects of leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons in mice. J Clin Invest (2008) 2.77
The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell (2013) 2.70
Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest (2002) 2.65
Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci Signal (2010) 2.64
Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem (2005) 2.60
Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer (2013) 2.59
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov (2012) 2.53
The Mycobacterium tuberculosis serine/threonine kinases PknA and PknB: substrate identification and regulation of cell shape. Genes Dev (2005) 2.52
Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2001) 2.49
Biomolecular characterization and protein sequences of the Campanian hadrosaur B. canadensis. Science (2009) 2.48
Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol (2002) 2.42
Cdk1/Erk2- and Plk1-dependent phosphorylation of a centrosome protein, Cep55, is required for its recruitment to midbody and cytokinesis. Dev Cell (2005) 2.40
Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell (2012) 2.39
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell (2013) 2.38
Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys (2011) 2.34
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J (2009) 2.33
Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol Cell (2011) 2.32
IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway. Mol Cell Biol (2007) 2.31
Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem (2001) 2.31
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet (2013) 2.29
Metabolic flux and the regulation of mammalian cell growth. Cell Metab (2011) 2.27
Centrosomal proteins CG-NAP and kendrin provide microtubule nucleation sites by anchoring gamma-tubulin ring complex. Mol Biol Cell (2002) 2.26
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2010) 2.21
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest (2011) 2.20
Regulation of epithelial tight junction assembly and disassembly by AMP-activated protein kinase. Proc Natl Acad Sci U S A (2007) 2.20
Overview of the Alliance for Cellular Signaling. Nature (2002) 2.15
Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions. J Biol Chem (2003) 2.12
A label-free quantification method by MS/MS TIC compared to SILAC and spectral counting in a proteomics screen. Proteomics (2008) 2.11
Coordinated regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains. Mol Cell Biol (2007) 2.06
High-resolution multi-dimensional NMR spectroscopy of proteins in human cells. Nature (2009) 2.06
The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J Cell Biol (2005) 2.04
mTOR drives its own activation via SCF(βTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Mol Cell (2011) 2.03
Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02